Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index
- PMID: 23540907
- PMCID: PMC3783412
- DOI: 10.1016/j.biopsych.2013.02.017
Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index
Erratum in
- Biol Psychiatry. 2015 Mar 15;77(6):597
Abstract
Background: Positron emission tomography research has shown that dopamine D2/3 receptor (D2/3R) availability is negatively correlated with body mass index (BMI) in obese but not in healthy subjects. However, previous positron emission tomography studies have not looked specifically at the ventral striatum (VS), which plays an important role in motivation and feeding. Furthermore, these studies have only used antagonist radiotracers. Normal-weight rats given free access to high-fat diets demonstrate behavioral sensitization to D2/3R agonists but not to antagonists. Sensitization is associated with increased D2/3R affinity, which affects binding of agonists but not antagonists.
Methods: We examined the association between BMI within the nonobese range (18.6-27.8) and D2/3R availability in the VS with the use of the agonist radiotracer [(11)C]-(+)-PHNO (n = 26) and the antagonist [(11)C]-raclopride (n = 35) in healthy humans.
Results: In the VS, we found a positive correlation between BMI and [(11)C]-(+)-PHNO binding but no relationship with [(11)C]-raclopride binding. Secondary analyses revealed no relationship between BMI and binding in the dorsal striatum with either radiotracer.
Conclusions: We propose that in nonobese individuals, higher BMI may be associated with increased D2R affinity in the VS. This increased affinity may potentiate the incentive salience of food cues and counteract the effects of satiety cues, thereby increasing feeding.
Keywords: Body mass index; Dopamine D(2) receptor; Food addiction; Obesity; PET; Ventral striatum.
Copyright © 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Dr. Nakajima reports having received grants from Japan Society for the Promotion of Science and Inokashira Hospital Research Fund and speaker’s honoraria from GlaxoSmith Kline, Janssen Pharmaceutical, Pfizer, and Yoshitomiyakuhin within the past 3 years. Dr. Graff-Guerrerro currently receives research support from the following external funding agencies: Canadian Institutes of Health Research, the U.S. National Institute of Health, and the Mexico Instituto de Ciencia y Tecnología para la Capital del Conocimiento en el Distrito Federal (ICyTDF). He has also received professional services compensation from Abbott Laboratories, Gedeon-Richter Plc, and Lundbeck; grant support from Janssen; and speaker compensation from Eli Lilly. Mr. Caravaggio, Ms. Raitsin, Dr. Gerretsen, and Dr. Wilson reported no biomedical financial interests or potential conflicts of interest.
Figures




Similar articles
-
Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.Hum Brain Mapp. 2015 Jul;36(7):2592-601. doi: 10.1002/hbm.22793. Epub 2015 Mar 18. Hum Brain Mapp. 2015. PMID: 25788222 Free PMC article.
-
Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.J Cereb Blood Flow Metab. 2015 Nov;35(11):1812-8. doi: 10.1038/jcbfm.2015.129. Epub 2015 Jun 10. J Cereb Blood Flow Metab. 2015. PMID: 26058690 Free PMC article.
-
Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.Biol Psychiatry. 2018 Oct 15;84(8):563-573. doi: 10.1016/j.biopsych.2018.05.014. Epub 2018 May 25. Biol Psychiatry. 2018. PMID: 30041971 Free PMC article.
-
Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies.J Labelled Comp Radiopharm. 2018 Mar;61(3):291-298. doi: 10.1002/jlcr.3558. Epub 2017 Sep 26. J Labelled Comp Radiopharm. 2018. PMID: 28857231 Review.
-
Central dopamine receptors: Radiotracers unveiling the Role of dopaminergic tone in obesity.J Mol Med (Berl). 2025 Jan;103(1):21-32. doi: 10.1007/s00109-024-02501-0. Epub 2024 Dec 4. J Mol Med (Berl). 2025. PMID: 39630278 Free PMC article. Review.
Cited by
-
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO.Neuropsychopharmacology. 2016 Dec;41(13):3042-3050. doi: 10.1038/npp.2016.115. Epub 2016 Jul 4. Neuropsychopharmacology. 2016. PMID: 27374277 Free PMC article.
-
DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.Mol Neurobiol. 2019 Sep;56(9):6512-6520. doi: 10.1007/s12035-019-1543-0. Epub 2019 Mar 8. Mol Neurobiol. 2019. PMID: 30847741
-
Basal Ganglia Dysfunction Contributes to Physical Inactivity in Obesity.Cell Metab. 2017 Feb 7;25(2):312-321. doi: 10.1016/j.cmet.2016.12.001. Epub 2016 Dec 29. Cell Metab. 2017. PMID: 28041956 Free PMC article.
-
Striatal dopamine tone is positively associated with adiposity in humans as determined by PET using dual dopamine type-2 receptor antagonist tracers.Mol Psychiatry. 2025 Aug;30(8):3708-3717. doi: 10.1038/s41380-025-02960-y. Epub 2025 Apr 6. Mol Psychiatry. 2025. PMID: 40188315 Free PMC article. Clinical Trial.
-
Neuroimaging and modulation in obesity and diabetes research: 10th anniversary meeting.Int J Obes (Lond). 2022 Apr;46(4):718-725. doi: 10.1038/s41366-021-01025-8. Epub 2021 Dec 21. Int J Obes (Lond). 2022. PMID: 34934178 Free PMC article. Review. No abstract available.
References
-
- Ogden CLCM, Kit BK, Flegal KM. Prevalence of Obesity in the United States, 2009–2010. NCHS Data Brief, No 82. Hyattsville, MD: National Center for Health Statistics; 2012. - PubMed
-
- Huang XF, Zavitsanou K, Huang X, Yu Y, Wang H, Chen F, et al. Dopamine transporter and D2 receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity. Behav Brain Res. 2006;175:415–419. - PubMed
-
- Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet. 2001;357:354–357. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources